Noerr advises Formycon AG on uplisting to the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange

Noerr has advised Formycon AG with a team led by partners Dr Julian Schulze De la Cruz and Dr Ralph Schilha on the admission of its shares to trading on the regulated market (Prime Standard) of the Frankfurt Stock Exchange ("Uplisting").

The shares of Formycon AG, previously traded on the open market (Scale) of the Frankfurt Stock Exchange, were admitted on 11 November 2024. The admission was based on a securities prospectus, which was approved by the German Federal Financial Supervisory Authority (BaFin) on 8 November 2024. M.M.Warburg & CO (AG & Co.) Kommanditgesellschaft auf Aktien is acting as listing agent for the Uplisting.

Formycon is a leading independent developer of high-quality biosimilars, follow-on products of biopharmaceutical drugs. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other important indication areas and covers almost the entire value chain from technical development and clinical trials to submission and approval by the drug authorities.

The Noerr team advised Formycon comprehensively on the transaction, in particular on the preparation of the securities prospectus and on capital market compliance and corporate governance issues. Noerr regularly advises Formycon on stock corporation and capital markets law and had already advised Formycon, inter alia, on the 2024 Annual General Meeting and on the entry of the investor Gedeon Richter via a capital increase in January 2024.

Advisor to Formycon AG: Noerr Partnerschaftsgesellschaft mbB

Lead: Dr Julian Schulze De la Cruz (partner, Capital Markets, Frankfurt), Dr Ralph Schilha (partner, Corporate, Munich)

Capital Markets: Dr Holger Alfes (partner), Dr Philip Schmoll (associated partner), Sebastian de Schmidt (counsel), Dr Thomas Thies (senior associate), Jens M. Göb (senior associate, all Frankfurt), Juri Stremel (senior associate, Hamburg), Alison Heinze (US Senior associate, Berlin)

Corporate: Dominique Wunderlich (associated partner, Frankfurt), Dr Christian Haagen (senior associate, Munich), Dr Jan Hoffmann Linhard (senior associate, Hamburg)

Finance: Dr Nikolai Warneke (partner, Frankfurt), Paulina von Hülsen (associate), Jonas Zinkand (associate, all Frankfurt)

Tax: Dr Martin Haisch (partner, Frankfurt)

Life Science: Dr Ralph Nack (partner, Munich), Evelyn Schulz (partner, Dresden), Dr Armin Kühne (associated partner, Munich)

Digital Business: Christian Alexander Mayer (partner), Dr Korbinian Hartl (associated partner), Alexander Brandt (senior associate, all Munich), Theresa Vera Möller (senior associate, Dresden)

Labour law: Dr Johannes Allmendinger (associated partner, Frankfurt)

Foreign trade law & investment control: Dr Bärbel Sachs (partner), Dr David Rösch (senior associate, Berlin)

Data protection: Dr Daniel Rücker (partner), Julian Monschke (associated partner, Frankfurt), Mirjam Lück (senior associate, both Munich)

Financial regulatory law: Dr Jens H. Kunz (partner, Frankfurt)

Competition law: Dr Fabian Badtke (partner, Frankfurt)

Compliance: Dr Ingo Theusinger (partner, Düsseldorf), Karolin Fitzer (associated partner, Frankfurt)

Inhouse Formycon AG: Dr Caroline Redeker (General Counsel)